{"id":"f14","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":{"setId":"bf517ae5-84e8-5e7e-e053-2a95a90af220","title":"F14 INCDNT-RLS (ARNICA MONTANA, ARNICA MONTANA, CALOCHORTUS GUNNISONII, CHERRY PLUM, CLEMATIS VITALBA, DICENTRA FORMOSA, EHRENDORFERIA CHRYSANTHA, ENGLISH HAWTHRON, HYPERICUM PERFORATUM, IGNATIA AMARA, IMPATIENS GLANDULIFERA, ORNITHOGALUM UMBELLATUM, PRUNELLA VULGARIS, ROCKROSE, RUTA GRAVEOLENS, STAPHYSAGRIA) SOLUTION/ DROPS [APEX ENERGETICS INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"F14 binds to FGFR on immune and synovial cells, blocking FGF-mediated signaling that drives inflammation and joint destruction in rheumatoid arthritis. By inhibiting this pathway, the drug reduces pro-inflammatory cytokine production and synovial cell activation, thereby decreasing joint inflammation and slowing disease progression.","oneSentence":"F14 is a humanized monoclonal antibody that targets and inhibits fibroblast growth factor receptor (FGFR) signaling to reduce inflammatory responses in arthritis.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:44:23.228Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"}]},"trialDetails":[{"nctId":"NCT05603832","phase":"PHASE3","title":"A Phase 3 Study of F14 for Management of Pain Following Total Knee Replacement","status":"COMPLETED","sponsor":"Arthritis Innovation Corporation","startDate":"2022-11-17","conditions":"Post Operative Pain","enrollment":151},{"nctId":"NCT04860635","phase":"PHASE2, PHASE3","title":"Safety of F14 Following Total Knee Replacement","status":"SUSPENDED","sponsor":"Arthritis Innovation Corporation","startDate":"2026-09","conditions":"Analgesia","enrollment":100},{"nctId":"NCT02074553","phase":"PHASE1","title":"A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-02","conditions":"Healthy Volunteer","enrollment":97},{"nctId":"NCT03541655","phase":"PHASE2","title":"Safety and Activity of F14 for Management of Pain Following Total Knee Replacement","status":"COMPLETED","sponsor":"Arthritis Innovation Corporation","startDate":"2018-05-04","conditions":"Total Knee Replacement, Postoperative Pain","enrollment":20},{"nctId":"NCT02760134","phase":"NA","title":"The Influence of SMP on Renal Pelvic Pressure In Vivo","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2016-04","conditions":"Renal Calculi","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":414,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"F14","genericName":"F14","companyName":"Arthritis Innovation Corporation","companyId":"arthritis-innovation-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"F14 is a humanized monoclonal antibody that targets and inhibits fibroblast growth factor receptor (FGFR) signaling to reduce inflammatory responses in arthritis. Used for Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}